Abstract:<p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p><p>With rapid lifestyle transitions, the increasing burden of nonalcoholic fatty liver disease (NAFLD) in China has emerged as a major public health issue. To obtain a comprehensive overview of the status of NAFLD over the past decade, we evaluated the epidemiology, risk factors, complications, and management of NAFLD in China through a systematic review and meta‐analysis. Five English literature databases and three Chinese databases were searched for relevant topics from 2008 to 2018. A total of 392 studies were included, with a population of 2,054,554 from 28 provinces and districts. National prevalence of NAFLD was 29.2%, with a heavier disease burden among the middle‐aged, males, those in northwest China and Taiwan, regions with a gross domestic product (GDP) per capita greater than 100,000 yuan, and Uygur and Hui ethnic groups. Currently, original studies on natural history and complications of NAFLD in China are scarce. Several studies revealed NAFLD is positively correlated with the incidence of extrahepatic tumors, diabetes, cardiovascular disease (CVD) and metabolic syndrome (MetS). The Chinese population may have a higher hereditary risk of NAFLD due to more frequent nonsynonymous mutations in genes regulating lipid metabolism. Ultrasonography is the primary imaging tool in the detection of NAFLD in China. Serum tests and risk stratification algorithms for staging NAFLD remain under investigation. Specific pharmaceutical treatments for NAFLD are still undergoing clinical trials. It is noteworthy that the Chinese are underrepresented compared to their proportion of the NAFLD population in such trials.</p><h3> Conclusion</h3><p>China experienced an unexpected rapid increase in the burden of NAFLD over a short period. Rising awareness and urgent actions need to be taken in order to control the NAFLD pandemic in China.</p><p>This article is protected by copyright. All rights reserved.</p>

Epidemiological Features of NAFLD From 1999 to 2018 in China

Unexpected Rapid Increase in the Burden of NAFLD in China From 2008 to 2018: A Systematic Review and Meta‐Analysis

Epidemiological Characteristics and Management of Nonalcoholic Fatty Liver Disease/nonalcoholic Steatohepatitis in China: A Narrative Review

General Characteristics and Clinical Practices of Chinese Patients with Non-Alcoholic Fatty Liver Disease

Burden of Liver Complications Related to Non‐alcoholic Fatty Liver Disease in China from 2005 to 2019: Observations from the Global Burden of Disease Study, 2019

Research Progress on Non-Alcoholic Fatty Liver Disease

Current status of research on nonalcoholic fatty liver disease in China

Worldwide long-term trends in the incidence of nonalcoholic fatty liver disease during 1990–2019: A joinpoint and age-period-cohort analysis

Time To Step-Up The Fight Against Nafld

Prevalence and Risk Factors for the Development of Nonalcoholic Fatty Liver Disease in a Nonobese Chinese Population: the Zhejiang Zhenhai Study.

Global incidence of NAFLD: Sets alarm bells ringing about NAFLD in China again

Estimating global prevalence, incidence, and outcomes of non-alcoholic fatty liver disease from 2000 to 2021: systematic review and meta-analysis

Epidemiology of alcoholic and nonalcoholic fatty liver disease in China

2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis

Risk factors for non-alcoholic fatty liver disease in a Chinese population.

Risk factors and biomarkers of non-alcoholic fatty liver disease: an observational cross-sectional population survey

Nonalcoholic fatty liver in Asia: Firmly entrenched and rapidly gaining ground

Advances in the Diagnosis and Treatment of Non-Alcoholic Fatty Liver Disease

Diagnosis and management of non-alcoholic fatty liver disease and related metabolic disorders: consensus statement from the Study Group of Liver and Metabolism, Chinese Society of Endocrinology.

Prevalence and Incidence of Non-alcohol Fatty Liver Disease in Chronic Hepatitis B Population in Southeast China: A Community-Based Study